CA Patent

CA2491733A1 — Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders

Assigned to Merck Sharp and Dohme LLC · Expires 2004-02-05 · 22y expired

What this patent protects

A class of benzodihydrofuran compounds having the structure of formula (I) below and pharmaceutically acceptable salts thereof are useful as therapeuti c compounds, particularly in the treatment of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and…

USPTO Abstract

A class of benzodihydrofuran compounds having the structure of formula (I) below and pharmaceutically acceptable salts thereof are useful as therapeuti c compounds, particularly in the treatment of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delayi ng the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, such as atherosclerosis.

Drugs covered by this patent

Patent Metadata

Patent number
CA2491733A1
Jurisdiction
CA
Classification
—
Expires
2004-02-05
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.